{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.4","upperLimit":"19.3","value":"14.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"title":"Total participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.1","upperLimit":"17.7","value":"14.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Participants >= 55 years old"},{"categories":[{"measurements":[{"comment":"Number of deaths was 4 until the study completion, not enough for OS calculation.","groupId":"OG000","lowerLimit":"11.0","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Participants < 55 years old"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"description":"OS was defined as duration from the date of randomization to the date of death from any cause. Kaplan-Meier (KM) method was used to estimate median OS. In this method, every participant had a follow-up time which was associated with an indicator, 1=event (death in our case), and 0 =censored. If the participants were not known to have died, time to date of last known to be alive was used as to calculate the follow-up time and indicator was 0 for these participants. KM method estimates the median OS based on the K-M curve. The K-M curve only drops when we had an event and censor data are the ticks in the graph. To estimate median OS, the K-M curve usually will be smoothed first and a line will be drawn at 50%. The median OS is the point when K-M curve and the horizontal hit. Survival status was collected every month for the first 2 months after discontinuation of study treatment and thereafter every 2 months until death or 4 years from each participant's first dose.","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine), followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m\\^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m\\^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1, 3, and 5 at a dose of 1 g/m\\^2 administered as a 3-hour IV infusion every 12 hours (2 g/m\\^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.","id":"OG000","title":"Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin"}],"paramType":"MEDIAN","populationDescription":"Full analysis set: all enrolled participants of Phase 2 Fit arm who received at least 1 dose of study medication. Number of participants analyzed signifies number of participants who were evaluable for this outcome measure. Number analyzed refers to number of participants evaluable for specified rows of categories.","reportingStatus":"POSTED","timeFrame":"First dose to Follow-up (4 years)","title":"Overall Survival (OS) at Phase 2 Fit","type":"SECONDARY","unitOfMeasure":"Months"}